IFPMA 2014 interview series ‘The Value of investing in immunization’
Immunization has shown excellent results against infectious diseases such as polio and measles, but continued success requires sustained political and financial commitment. Unfortunately, immunization as a whole remains an unfinished business as too many children are still dying of vaccine preventable diseases. As President and General Manager of Pfizer’s Vaccines and an IFPMA Vaccine CEO Steering Committee member, Ms Susan Silbermann talks about why investing in vaccines is so valuable and how the effective introduction and rollout of new vaccines can save millions of more lives.
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
Learn more
Related news and resources
The socio-economic value of adult immunisation programmes
Download this OHE report, commissioned by IFPMA, to learn more about the socio-economic value of adult vaccination programems on individual lives and societies at large.
Read more
Open letter from the biopharmaceutical industry to G20 Ministers in support of the advancement of the G20 Health Agenda
On 9 April 2024, IFPMA, Interfarma, and FIFARMA submitted an open letter to G20 Ministers in support of the advancement of the G20 Health Agenda. The letter is available for download in English, Portuguese, and Spanish.
Read moreIFPMA Statement at the closing of the WTO Ministerial Conference in Abu Dhabi
On 1 March, at the end of the 13th WTO Ministerial Conference, IFPMA issued a statement.
Read more